Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Authors
Burza, SakibSinha, Prabhat K
Mahajan, Raman
Lima, María Angeles
Mitra, Gaurab
Verma, Neena
Balsegaram, Manica
Das, Pradeep
Issue Date
2014-01
Metadata
Show full item recordJournal
PLoS Neglected Tropical DiseasesAbstract
A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen.Publisher
Public Library of SciencePubMed ID
24392166Language
enISSN
1935-2735ae974a485f413a2113503eed53cd6c53
10.1371/journal.pntd.0002536